NEW YORK (AP) — Novo Nordisk AS says the Food and Drug Administration rejected its applications for approval of once-per-day insulin drugs to treat diabetes.
The Danish drugmaker says it received a "complete response letter" from the FDA regarding its applications for approval of Tresiba and Ryzodeg, or insulin degludec, on Friday. Such a letter indicates the agency determined the application cannot be approved in its current form.
In November, panel of federal health advisers recommended that the government approve degludec. The FDA is not required to follow the group's advice, but it often does.
Tresiba contains long-acting insulin, and Ryzodeg contains both long- and short-acting insulins.
Diabetics either do not produce enough of the hormone insulin or do not use it efficiently, allowing excess sugar, or glucose, to accumulate in the blood.
Oregon Town Blasts Obama's "Inappropriate," "Disrespectful" Visit After College Shooting - Bearing Arms - Barack Obama, Mass shootings, Umpqua Community College
Watch Mika Brzezinski explain how AR 15s can “blow up animals”
SHAMEFUL: Hillary Clinton's latest 'faith' claim may be her most infuriating one yet; What about THIS? - twitchy.com
The New Norm?
Crony Capitalism Driving Nevada Energy Controversy | Human Events
The Russian infringement of Turkish airspace is bigger than it seems | RedState
Thomas Sowell - Charlatans and Sheep